The newly cloned tumor-reactive gp100 TCRs restricted by four different class I alleles (A*24:02, B*40:01, C*06:02, and C*07:01) could substantially extend the applicability of ImmTAC therapy targeting gp100. This evidence concerns the gene PMEL and neoplasm.